siRNA as a new drug: Intellectual property

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 2, 2005, Pages 141-152

  Schiffelers, Raymond M ^a   van Kolfschoten, Sarianne C ^a   van Dijk, Maarten ^a   Scaria, Putthupparampil V ^b   Woodle, Martin C ^b   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Intradigm Corporation   (United States)

Author keywords

Chemical modification; Double stranded RNA; Drug delivery; Gene silencing; RNA interference (RNAi); Small interfering RNA (siRNA)

Indexed keywords

ATAXIN 1; CHOLESTEROL; CHYLOMICRON; DENDRIMER; DNA; DOUBLE STRANDED RNA; GREEN FLUORESCENT PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HISTIDINE; HOX PROTEIN; INTERLEUKIN 12; LACTOSE; LIPOSOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSINE; MACROGOL; MONOMER; NEW DRUG; NUCLEIC ACID; POLYETHYLENEIMINE; POLYGLUTAMINE; POLYPEPTIDE; PROTEIN KINASE; PROTEIN VP22; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; TIOPRONIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS VECTOR;

CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG STABILITY; DRUG TARGETING; GENE FUNCTION; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HYDRODYNAMICS; MICROINJECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATENT; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPRODUCIBILITY; REVIEW; SEQUENCE ANALYSIS; TARGET CELL; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

EID: 14544278357     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.2.141     Document Type: Review

References (85)

1. CAPLEN NJ: Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. (2004) 11:1241-1248.
2. DOWNWARD J: RNA interference. Br. Med. J. (2004) 328 1245-1248.
3. MONTGOMERY MK: RNA interference: historical overview and significance. Methods Mol. Biol. (2004) 265:3-21.
4. MEDEMA RH: Optimizing RNA interference for application in mammalian cells. Biochem. J. (2004) 380:593-603.
5. DUXBURY MS, WHANG EE: RNA interference: a practical approach. J. Surg. Res. (2004) 117:339-344.
6. KAWASAKI H, TAIRA K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature (2004) 431:211-217.
7. MORRIS KV, CHAN SW, JACOBSEN SE, LOONEY DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 305:1289-1292.
8. PAL-BHADRA M, BHADRA U, BIRCHLER JA: RNAi related mechanisms affect both transcriptional and post-transcriptional transgene silencing in Drosophila. Mol. Cell. (2002) 9:315-327.
9. ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498.
10. KUMAR M, CARMICHAEL GG: Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol. Mol. Biol. Rev. (1998) 62:1415-1434.
11. JACOBS BL, LANGLAND JO: When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology (1996) 219:339-349.
12. ELBASHIR SM, LENDECKEL W, TUSCHL T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15 188-200.
13. MEISTER G, LANDTHALER M, PATKANIOWSKA A, DORSETT Y, TENG G, TUSCHL T: Human Argonaute-2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell. (2004) 15:185-197.
14. FIRE A: RNA-triggered gene silencing. Trends Genet. (1999) 15:358-363.
15. MONTGOMERY MK, XU S, FIRE A: RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA (1998) 95:15502-15507.
16. TIMMONS L, FIRE A: Specific interference by ingested dsRNA. Nature (1998) 395:854-857.
17. MONTGOMERY MK, FIRE A: Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. (1998) 14:255-258.
18. FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806-811.
19. SIJEN T, FLEENOR J, SIMMER F et al.: On the role of RNA amplification in dsRNA-triggered gene silencing. Cell (2001) 107 465-476.
20. NISHIKURA K: A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell (2001) 107:415-418.
21. BALLEW NL: Benitec Ltd gene silencing from down under. Chem. Biol. (2004) 11:285-286.
22. LI YX, FARRELL MJ, LIU R, MOHANTY N, KIRBY ML: Double-stranded RNA injection produces null phenotypes in zebrafish. Dev. Biol. (2000) 217:394-405.
23. WARGELIUS A, ELLINGSEN S, FJOSE A: Double-stranded RNA induces specific developmental defects in zebrafish embryos. Biochem. Biophys. Res. Commun. (1999) 263:156-161.
24. STEIN P. SVOBODA P, SCHULTZ RM: Transgenic RNAi in mouse oocytes: a simple and fast approach to study gene function. Dev. Biol. (2003) 256:187-93.
25. WIANNY F, ZERNICKA-GOETZ M; Specific interference with gene function by double-stranded RNA in early mouse development. Nat. Cell Biol. (2000) 2:70-75.
26. HAMMOND SM, BOETTCHER S, CAUDY AA, KOBAYASHI R, HANNON GJ: Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 293:1146-1150.
27. HAMMOND SM, CAUDY AA, HANNON GJ: Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet. (2001) 2 110-119.
28. BERNSTEIN E, CAUDY AA, HAMMOND SM, HANNON GJ; Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. (2001) 409:363-366.
29. HAMMOND SM, BERNSTEIN E, BEACH D, HANNON GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 404:293-296.
30. XU Y, LINDE A, LARSSON O et al.: Functional comparison of single- and double-stranded siRNAs in mammalian cells. Biochem. Biophys. Res. Commun. (2004) 316:680-687.
31. HOLEN T, AMARZGUIOUI M, BABAIE E, PRYDZ H: Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res. (2003) 31:2401-2407.
32. PANNIER AK, SHEA LD: Controlled release systems for DNA delivery. Mol. Ther. (2004) 10:19-26.
33. CROOKE ST: Antisense strategies. Curr. Mol. Med. (2004) 4:465-487.
34. JEPSEN JS, SORENSEN MD, WENGEL J: Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides (2004) 14:130-146.
35. LYSIK MA, WU-PONG S: Innovations in oligonucleotide drug delivery. J. Pharm. Sci. (2003) 92:1559-1573.
36. KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270 1628-1644.
37. GAMBARI R: Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr. Pharm. Des. (2001) 7:1839-1862.
38. LAMBERT G, FATTAL E, COUVREUR P: Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv. Drug Deliv. Rev. (2001) 47:99-112.
39. YUEN AR, SIKIC BI: Clinical studies of antisense therapy in cancer. Front Biosci. (2000) 5:D588-D5893.
40. AGRAWAL S, ZHAO Q: Antisense therapeutics. Curr. Opin. Chem. Biol. (1998) 2:519-28.
41. HARBORTH J, ELBASHIR SM, VANDENBURGH K et al.: Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. (2003) 13:83-105.
42. AOKI Y, CIOCA DP, OIDAIRA H, KAMIYA J, KIYOSAWA K: RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin. Exp. Pharmacol. Physiol. (2003) 30:96-102.
43. XU Y, ZHANG HY, THORMEYER D et al.: Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem. Biophys. Res. Commun. (2003) 306:712-717.
44. AMARZGUIOUI M, HOLEN T, BABAIE E, PRYDZ H: Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. (2003) 31:589-595.
45. HAMADA M, OHTSUKA T, KAWAIDA R et al.: Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. (2002) 12 301-309.
46. CZAUDERNA F, FECHTNER M, DAMES S et al.: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. (2003) 31:2705-2716.
47. LAYZER JM, MCCAFFREY AP, TANNER AK, HUANG Z, KAY MA, SULLENGER BA: In vivo activity of nuclease-resistant siRNAs. RNA (2004) 10:766-71.
48. HOLEN T, AMARZGUIOUI M, BABAIE E, PRYDZ H: Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res. (2003) 31:2401-2407.
49. CHIU YL, RANA TM: siRNA function in RNAi: a chemical modification analysis. RNA. (2003) 9:1034-1048.
50. YUAN B, LATEK R, HOSSBACH M, TUSCHL T, LEWITTER F: siRNA Selection server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. (2004) 32:W130-W134.
51. AMARZGUIOUI M, PRYDZ H: An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. (2004) 316:1050-1058.
52. LORENZ C, HADWIGER P, JOHN M, VORNLOCHER HP, UNVERZAGT C: Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. (2004) 14:4975-4977.
53. SOUTSCHEK J, AKINC A, BRAMLAGE B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432:173-8.
54. DORSETT Y, TUSCHL T: siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. (2004) 3:318-29.
55. SCHIFFELERS RM, WOODLE MC, SCARIA P: Pharmaceutical prospects for RNA interference. Pharm. Res. (2004) 21:1-7.
56. STEVENSON M: Therapeutic potential of RNA interference. N. Engl. J. Med. (2004) 351:1772-1777.
57. VERMA NK, DEY CS: RNA-mediated gene silencing: mechanisms and its therapeutic applications. J. Clin. Pharm. Ther. (2004) 29 395-404.
58. SCHERER L, ROSSI JJ: Recent applications of RNAi in mammalian systems. Curr. Pharm. Biotechnol. (2004) 5:355-560.
59. BRAASCH DA, PAROO Z, CONSTANTINESCU A et al.: Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem Lett. (2004) 14:1139-1143.
60. SONG E, LEE SK, WANG J et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. (2003) 9:347-351.
61. HAMAR P, SONG E, KOKENY G, CHEN A, OUYANG N, LIEBERMAN J: Small interfering RNA targeting Fas protects mice against renal ischaemia-reperfusion injury. Proc. Natl. Acad. Sci. USA (2004) 101:14883-14888.
62. GILADI H, KETZINEL-GILAD M, RIVKIN L, FELIG Y, NUSSBAUM O, GALUN E: Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. (2003) 8:769-776.
63. CONTRERAS JL, VILATOBA M, ECKSTEIN C, BILBAO G, ANTHONY THOMPSON J, ECKHOFF DE: Caspase-8 and caspase-3 small interfering RNA decreases ischaemia/reperfusion injury to the liver in mice. Surgery (2004) 136:390-400.
64. HAGSTROM JE, HEGGE J, ZHANG G et al.: A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol. Ther. (2004) 10:386-398.
65. CHAE SS, PAIK JH, FURNEAUX H, HLA T: Requirement for sphingosine 1-phosphate receptor-1 in tumour angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. (2004) 114 1082-1089.
66. NAKAMURA H, SIDDIQUI SS, SHEN X et al.: RNA interference targeting transforming growth factor-β Type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis. (2004) 10 703-711.
67. MINAKUCHI Y, TAKESHITA F, KOSAKA N et al.: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. (2004) 32:e109
68. HASSANI Z, LEMKINE GF, ERBACHER P et al. Lipid-mediated siRNA delivery downregulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. (2004) [Epub ahead of print].
69. SORENSEN DR, LEIRDAL M, SIOUD M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol Biol. (2003) 327:761-766.
70. GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA (2004) 101:8676-8681.
71. KIM B, TANG Q, BISWAS PS et al.: Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor-pathway genes; therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. (2004) 165:2177-2185.
72. SCHIFFELERS RM, ANSARI A, ZHOU Q et al.: Cancer siRNA therapy by tumour selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. (2004) 32:e149.
73. TOMANIN R, SCARPA M: Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr. Gene Ther. (2004) 4:357-372.
74. WALTHER W, STEIN U: Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs (2000) 60 249-71.
75. WILSON DR: Viral-mediated gene transfer for cancer treatment. Curr. Pharm. Biotechnol. (2002) 3:151-164.
76. DOBBELSTEIN M: Viruses in therapy - royal road or dead end? Virus Res. (2003) 92:219-221.
77. XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. (2002) 20 1006-1010
78. XIA H, MAO Q, ELIASON SL et al.: RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. (2004) 10:816-820.
79. BAIN JR, SCHISLER JC, TAKEUCHI K, NEWGARD CB, BECKER TC: An adenovirus vector for efficient RNA interference-mediated suppression of target genes in insulinoma cells and pancreatic islets of Langerhans. Diabetes (2004) 53:2190-2194.
80. DUXBURY MS, ITO H, BENOIT E, ZINNER MJ, ASHLEY SW, WHANG EE: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. Surgery (2004) 136:261-269.
81. MORRIS KV, ROSSI JJ: Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Curr. HIV Res. (2004) 2:185-91.
82. LEE MT, COBURN GA, MCCLURE MO, CULLEN BR: Inhibition of human immunodeficiency virus Type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J. Virol. (2003) 77:11964-11972.
83. TOMAR RS, MATTA H, CHAUDHARY PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 22(36):5712-5715.
84. SIMEONI F, MORRIS MC, HEITZ F, DIVITA G: Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. (2003) 31:2717-2724.
85. BRUGIDOU J, LEGRAND C, MERY J, RABIE A: The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurons: a new basis for an efficient intracellular delivery system. Biochem. Biophys. Res. Commun. (1995) 214:685-693.